DionisieVFilipGAManeaMC, et al. The anti-inflammatory role of SSRI and SNRI in the treatment of depression: a review of human and rodent research studies. Inflammopharmacology. 2021;29(1):75-90.
2.
KostadinovIDelevDPetrovaA, et al. Study on anti-inflammatory and immunomodulatory effects of fluoxetine in rat models of inflammation. Eur J Inflamm. 2015;13(3):173-182.
3.
HoertelNRicoMSVernetR, et al. Association between SSRI antidepressant use and reduced risk of intubation or death in hospitalized patients with coronavirus disease 2019: a multicenter retrospective observational study. MedRxiv. 2020.
4.
OskotskyTMarićITangA, et al. Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants. JAMA Network Open. 2021;4(11):e2133090.
5.
CreedenJFImamiASEbyHM, et al. Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection. Biomed Pharmacother. 2021;138:111437.
6.
DechaumesANekouaMPBelouzardS, et al. Fluoxetine can inhibit SARS-CoV-2 in vitro. Microorganisms. 2021;9(2):339.
7.
SchloerSBrunotteLMecate-ZambranoA, et al. Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro. Br J Pharmacol. 2021;78:2339-2350.
8.
EugeneAR. Fluoxetine pharmacokinetics and tissue distribution suggest a possible role in reducing SARS-CoV-2 titers. F1000Research. 2021;10(477):477.
9.
SchloerSBrunotteLGoretzkoJ, et al. Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine. Emerg Microbes Infect. 2020;9(1):2245-2255.
10.
PashaeiY. Drug repurposing of selective serotonin reuptake inhibitors: could these drugs help fight COVID-19 and save lives?. J Clin Neurosci. 2021;88:163-172.
11.
FondGNemaniKEtchecopar-EtchartD, et al. Association between mental health disorders and mortality among patients with COVID-19 in 7 countries: a systematic review and meta-analysis. JAMA Psychiat. 2021;78(11):1208-1217.
12.
KabingerFStillerCSchmitzováJ, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28:1-7.
13.
FischerWAEronJJHolmanW, et al. Molnupiravir, an oral antiviral treatment for COVID-19. MedRxi.v2021.
